DURECT Corporation (DRRX): Price and Financial Metrics


DURECT Corporation (DRRX)

Today's Latest Price: $2.19 USD

0.11 (-4.78%)

Updated Jan 27 4:00pm

Add DRRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

DRRX Stock Summary

  • Of note is the ratio of Durect Corp's sales and general administrative expense to its total operating expenses; only 17.17% of US stocks have a lower such ratio.
  • With a price/sales ratio of 11.13, Durect Corp has a higher such ratio than 84.04% of stocks in our set.
  • As for revenue growth, note that DRRX's revenue has grown 86.56% over the past 12 months; that beats the revenue growth of 93.78% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Durect Corp, a group of peers worth examining would be IPHA, PULM, BCRX, VIE, and PZG.
  • DRRX's SEC filings can be seen here. And to visit Durect Corp's official web site, go to www.durect.com.

DRRX Stock Price Chart Interactive Chart >

Price chart for DRRX

DRRX Price/Volume Stats

Current price $2.19 52-week high $2.96
Prev. close $2.30 52-week low $0.95
Day low $2.12 Volume 1,185,590
Day high $2.32 Avg. volume 874,453
50-day MA $2.04 Dividend yield N/A
200-day MA $2.06 Market Cap 444.96M

DURECT Corporation (DRRX) Company Bio


DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.


DRRX Latest News Stream


Event/Time News Detail
Loading, please wait...

DRRX Latest Social Stream


Loading social stream, please wait...

View Full DRRX Social Stream

Latest DRRX News From Around the Web

Below are the latest news stories about Durect Corp that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

Dosing underway in DURECT's DUR-928 mid-stage study in alcoholic hepatitis

DURECT ([[DRRX]] +3.6%) has dosed the first patient in its AHFIRM Phase 2b study evaluating its lead candidate, DUR-928 in severe alcohol-associated hepatitis ((AH)) patients.In this placebo-controlled 300-subject study, the company will evaluate 90-day survival rate for patients treated with DUR-928 compared to those treated with placebo plus standard of care. Secondary endpoints...

Seeking Alpha | January 25, 2021

DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis

DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients.

Yahoo | January 25, 2021

Transdermal and Transmucosal Drug Delivery Systems Market - Awareness Insights 2025 | Aveva Drug Delivery Systems, 3M Pharmaceuticals, DURECT Corporation, ALZA Corporation

Global Transdermal and Transmucosal Drug Delivery Systems Market: Snapshot Transdermal and transmucosal drug delivery systems as alternative drug delivery routes have gained traction in clinical practices over the past few decades. The need for these systems is driven by the growing

OpenPR | January 6, 2021

DURECT Corporation Appoints Two New Board Members

DURECT Corporation (Nasdaq: DRRX) today announced the appointment of two new members to its board of directors, Gail J. Maderis, MBA and Mohammad Azab, M.D., M. Sc., MBA, two senior industry veterans with extensive drug development, clinical research and medical affairs experience.

Yahoo | January 5, 2021

DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was…

PR Newswire | January 4, 2021

Read More 'DRRX' Stories Here

DRRX Price Returns

1-mo 4.29%
3-mo 24.43%
6-mo 11.73%
1-year 9.50%
3-year 76.61%
5-year 82.50%
YTD 5.80%
2020 -45.53%
2019 691.67%
2018 -47.83%
2017 -31.34%
2016 -39.37%

Continue Researching DRRX

Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:

Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8033 seconds.